对于痴呆症认知和功能结果的运动干预:系统性审查和分析,探索剂量指标,异质性和与实施相关的因素
Chun-Wei Lu1, Tsz-Ching Ng1, Yi-Chen Cheng2
1Graduate Institute of Sport Coaching Science, Chinese Culture University, Taipei 111369, Taiwan.
Healthcare (Basel, Switzerland)
|March 14, 2026
概括
运动干预措施对老年痴呆症患者的认知和功能产生了有限而多样化的影响. 没有支持一致的剂量反应关系,这表明上下文和质量是关键.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 运动科学 运动科学
背景情况:
- 运动是一种非药物治疗方法,用于老年痴呆症患者的认知和功能支持.
- 现有文献显示异质效应,基于时间的剂量标记可能不足以解释试验变异性.
研究的目的:
- 对老年痴呆症患者的运动干预措施的随机对照试验进行系统审查和元分析.
- 评估线性剂量指标是否解释干预对认知,功能或行为结果影响的异质性.
主要方法:
- 按照PRISMA 2020指南进行系统审查和元分析.
- 包括随机对照试验评估老年痴呆症患者结构化炼.
- 随机效应元分析和元回归来分析聚合效应和剂量反应关系.
主要成果:
- 分析了22项研究,发现固定效应模型的小,统计学上显著的改善,但不是随机效应模型.
- 在研究之间观察到适度的异质性 (I2 = 51.757%).
- 线性剂量指标没有显著地解释异质性,表明剩余变异性.
结论:
- 目前的证据表明,运动对老年痴呆症患者的认知和功能的影响有限且异质.
- 不支持一致的线性剂量反应关系.
- 练习策略的有效性可能取决于可行性和监督质量,强调具体上下文的方法而不是严格的剂量依赖.
关键词:
坚持性 坚持性认知结果的认知结果痴呆症 痴呆症是一种痴呆症.功能性结果的结果.健康的衰老健康的衰老不同质性的异质性实施实施实施实施实施.这是一个元分析.这是一种元回归的元回归.结构化炼是一种结构化的炼.更多相关视频
07:27Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
11.0K
07:01Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
Published on: September 20, 2020
5.3K
相关概念视频
Cognitive Development During Adulthood
1.1K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Dementia
656
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
656
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
793
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
793
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
